15 June 2018 | News
The CMUH will provide professional and medical clinical trial advice to the Novotech team.
Image credit- medianet.com.au
Asia-Pacific specialist CRO Novotech has signed a Memorandum of Understanding (MoU) with the China Medical University Hospital (CMUH) in Taiwan to facilitate high-quality and rapid feasibility, start-up and recruitment processes.
The CMUH deal is designed to give Novotech clients faster start-up times, access to the CMUH patient database, world-class clinical research, regulatory compliance with FDA, PMDA and EMEA, outstanding recruiters across many therapeutic areas such as breast cancer, lung cancer, colorectal cancer, Hepatitis, SLE, RA, Stroke, Diabetes, etc., and leading principal investigators.
Under the terms of the MoU, the CMUH will provide professional and medical clinical trial advice to the Novotech team including feasibility, principal investigator selection, and assistance with patient recruitment. Novotech will promote the clinical research capabilities of CMUH internationally, in particular their Phase 1 unit.
The CMUH is a 2,054-bed facility with a dedicated Clinical Trials Centre (CTC). The CTC of CMUH was established in 2008 and has been led by distinguished Professor Chung Y. Hsu since 2010.